Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovAliX has signed a fragment-based drug discovery alliance with Kyowa Hakko Kirin to develop new drug candidates targeting protein-protein interactions.
Subscribe to our email newsletter
NovAliX will employ its biophysical capabilities and medicinal chemistry potential in producing the lead candidates.
NovAliX president Stephan Jenn said, "This drug discovery collaboration with a leading Japanese pharmaceutical company also confirms the quality of our discovery platforms and its ability to deliver valuable lead candidates."
According to the deal, NovAliX is eligible for technology access fees in addition to research funding payments and milestone payments.